Eculizumab is well-tolerated and shows significant improvement in PNH patients (Ph III)
In a Phase III study, eculizumab provided clinically and statistically significant improvements in intravascular hemolysis, anemia, fatigue and quality of life in patients with paroxysmal nocturnal hemoglobinuria. Eculizumab therapy also reduced adverse events and showed significant benefits in patient-reported outcomes.